Participants with unexplained anemia, and/or thrombocytopenia
Uncontrolled autoimmune hemolytic anemia or thrombocytopenia.
Clinically significant anemia, neutropenia or thrombocytopenia at screening
History of autoimmune hemolytic anemia or autoimmune thrombocytopenia.
Untreated autoimmunity such as autoimmune hemolytic anemia, or immune thrombocytopenia
Uncontrolled autoimmune hemolytic anemia or thrombocytopenia
Uncontrolled autoimmune hemolytic anemia or thrombocytopenia
Active and uncontrolled autoimmune hemolytic anemia (AIHA) or autoimmune thrombocytopenia (ITP) requiring daily prednisone dose of >=  mg.
Patients should not have active or uncontrolled autoimmune hemolytic anemia or immune thrombocytopenia
Active, uncontrolled autoimmune phenomenon (autoimmune hemolytic anemia or immune thrombocytopenia) requiring steroid therapy >  mg prednisone daily or equivalent, within  days of starting venetoclax
Patients that have active hemolytic anemia
Active, uncontrolled autoimmune hemolytic anemia or immune thrombocytopenia requiring steroid therapy
Active, uncontrolled autoimmune phenomenon (autoimmune hemolytic anemia or immune thrombocytopenia) requiring steroid therapy with >  mg daily of prednisone dose or equivalent
Patients that have active hemolytic anemia
Active, uncontrolled autoimmune phenomenon (autoimmune hemolytic anemia or immune thrombocytopenia) requiring steroid therapy
Active autoimmune disorder (with the exception of autoimmune hemolytic anemia or ITP)
MRI MONITORING SUB-STUDY: Known history of severe renal insufficiency, asthma, allergic conditions, sickle cell anemia, chronic hemolytic anemia, and gastrointestinal disorders
Active, uncontrolled autoimmune hemolytic anemia or immune thrombocytopenia requiring steroid therapy
Autoimmune anemia and/or thrombocytopenia poorly responsive to corticosteroids or other standard therapy
No clinically apparent alternative explanation for thrombocytopenia and anemia
Patients who exhibit any active or on-going autoimmune processes including, but not limited to, autoimmune hemolytic anemia or immune thrombocytopenia purpura, are NOT eligible for participation
Patients with uncontrolled Autoimmune Hemolytic Anemia (AIHA) or autoimmune thrombocytopenia (ITP).
Patients with active autoimmune anemia or autoimmune thrombocytopenia are NOT eligible
Uncontrolled autoimmune hemolytic anemia or thrombocytopenia
Autoimmune anemia or thrombocytopenia that is poorly responsive to corticosteroids
Patients that have active hemolytic anemia
Known clinically significant anemia due to iron, vitamin B, or folate deficiencies, or autoimmune or hereditary hemolytic anemia, or gastrointestinal bleeding
Autoimmune anemia and/or thrombocytopenia that is poorly responsive to corticosteroids or other standard therapy.
Patients with uncontrolled autoimmune hemolytic anemia (AIHA) or autoimmune thrombocytopenia (ITP)
Uncontrolled autoimmune hemolytic anemia or thrombocytopenia
History of autoimmune hemolytic anemia or autoimmune thrombocytopenia.
Untreated autoimmunity such as autoimmune hemolytic anemia, or immune thrombocytopenia
Active, uncontrolled autoimmune hemolytic anemia or immune thrombocytopenia requiring steroid therapy
Uncontrolled autoimmune hemolytic anemia or thrombocytopenia
History of hemolytic anemia or thalassemia
Participants with uncontrolled autoimmune hemolytic anemia or immune thrombocytopenia
Uncontrolled autoimmune hemolytic anemia or thrombocytopenia
Patients with uncontrolled autoimmune hemolytic anemia or autoimmune thrombocytopenia
Patients with uncontrolled autoimmune hemolytic anemia (AIHA) or autoimmune thrombocytopenia (ITP)
Patients that have active hemolytic anemia
Uncontrolled autoimmune hemolytic anemia or thrombocytopenia
Uncontrolled autoimmune hemolytic anemia or thrombocytopenia
Uncontrolled autoimmune anemia or thrombocytopenia
Suffering from an autoimmune disease (including refractory immune thrombocytopenia-ITP or refractory autoimmune hemolytic anemia-AIHA)
Patients with autoimmune hemolytic anemia or autoimmune thrombocytopenia will be eligible for treatment
Has autoimmune cytopenia (anemia, thrombocytopenia, leukopenia).
Thrombocytopenia (<,/uL)
total bilirubin ?. X institutional ULN unless due to Gilbert's syndrome, controlled autoimmune hemolytic anemia or immune thrombocytopenia
Active autoimmune haemolytic anemia.
Active autoimmune thrombocytopenia.
Known active, uncontrolled autoimmune hemolytic anemia or immune thrombocytopenia requiring steroid therapy
Thrombocytopenia
Hemolytic anemia
Active hemolytic anemia
Patients with sickle cell anemia and other hemolytic anemia
Subjects with Gilbert's syndrome or resolving autoimmune hemolytic anemia may have a bilirubin up to . x ULN and are still eligible